New study aims to perfect dosing of common staph infection drug
NCT ID NCT06848387
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study measures the amount of free cloxacillin in the blood of adults receiving the drug as a continuous infusion for severe staph infections. Researchers want to ensure levels are not too high or too low. They will use this data to create a model that predicts the right dose based on age, kidney function, and other factors. The study involves 25 participants and is currently recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- cloxacillin
- What this could lead to
- If successful, this could lead to more personalized dosing of cloxacillin for severe staph infections, improving safety and effectiveness.
- What could go wrong
- This is a small, early-phase study with only 25 participants, so results may not apply to everyone. It is designed to gather data, not to test a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAPHYLOCOCCAL INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Västmanlands sjukhus Västerås
RECRUITINGVästerås, Sweden
More trials for these conditions
Other studies related to the condition(s) this trial covers.